Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a …
PM Morice, A Leary, C Dolladille, B Chrétien… - The Lancet …, 2021 - thelancet.com
Background Poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy and
acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some …
acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some …
[HTML][HTML] Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials
Cervical cancer constitutes a significant health burden for women globally. While most
patients with early-stage disease can be cured with radical surgery or chemoradiotherapy …
patients with early-stage disease can be cured with radical surgery or chemoradiotherapy …
[HTML][HTML] Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
Background Niraparib is an oral poly (adenosine diphosphate [ADP]–ribose) polymerase
(PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We …
(PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We …
[HTML][HTML] Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
K Moore, N Colombo, G Scambia, BG Kim… - … England Journal of …, 2018 - Mass Medical Soc
Background Most women with newly diagnosed advanced ovarian cancer have a relapse
within 3 years after standard treatment with surgery and platinum-based chemotherapy. The …
within 3 years after standard treatment with surgery and platinum-based chemotherapy. The …
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up
N Colombo, C Creutzberg, F Amant, T Bosse… - International Journal of …, 2016 - ijgc.bmj.com
Abstract The first joint European Society for Medical Oncology (ESMO), European SocieTy
for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology …
for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology …
[HTML][HTML] Niraparib in patients with newly diagnosed advanced ovarian cancer
A González-Martín, B Pothuri, I Vergote… - … England Journal of …, 2019 - Mass Medical Soc
Background Niraparib, an inhibitor of poly (adenosine diphosphate [ADP]–ribose)
polymerase (PARP), has been associated with significantly increased progression-free …
polymerase (PARP), has been associated with significantly increased progression-free …
[HTML][HTML] Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
Background Olaparib has shown significant clinical benefit as maintenance therapy in
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 …
IE Krop, SB Kim, A González-Martín… - The Lancet …, 2014 - thelancet.com
Background Patients with progressive disease after two or more HER2-directed regimens for
recurrent or metastatic breast cancer have few effective therapeutic options. We aimed to …
recurrent or metastatic breast cancer have few effective therapeutic options. We aimed to …
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised …
S Banerjee, KN Moore, N Colombo, G Scambia… - The Lancet …, 2021 - thelancet.com
Background There is a high unmet need for treatment regimens that increase the chance of
long-term remission and possibly cure for women with newly diagnosed advanced ovarian …
long-term remission and possibly cure for women with newly diagnosed advanced ovarian …
[HTML][HTML] Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib …
A González-Martín, B Pothuri, I Vergote… - European Journal of …, 2023 - Elsevier
Purpose To report updated long-term efficacy and safety from the double-blind, placebo-
controlled, phase 3 PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016). Methods …
controlled, phase 3 PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016). Methods …